Tanvex BioPharma Appoints Stephen Lam As The New Chief Executive Officer

Tanvex BioPharma Inc., a biopharmaceutical company specializing in biosimilars and contract development and manufacturing (CDMO), has named Stephen Lam as its new Chief Executive Officer, effective September 5, 2024. Lam takes over from Henry Chen, who will continue in his role as Chairman until Tanvex finalizes its strategic partnership with Bora Pharmaceuticals Co., Ltd.

In his new role, Lam will lead the integration efforts with Bora, drive key strategic initiatives, and manage the company's daily operations, including global CDMO activities and the advancement of Tanvex’s biosimilar pipeline. With a distinguished career spanning over 35 years in the biopharmaceutical sector, including positions at Lonza, Amgen, and Patheon, Lam brings a proven track record of success. His most recent role was Vice President and General Manager, Head of Biologics at Thermo Fisher Scientific.

“I am honored to take on the role of CEO at Tanvex. By integrating Tanvex’s established commercial biologics manufacturing with Bora’s strong reputation, industry leading quality, and proven process development expertise,” said Lam, “We can serve our customers no matter where they are in their drug development lifecycle, from First-In-Human studies through to commercial launch.”